The 2021 top 100 bio­phar­ma in­vestors: As the pan­dem­ic hit and IPOs boomed, VCs swung in­to ac­tion like nev­er be­fore

The glob­al pan­dem­ic may have roiled economies, killed hun­dreds of thou­sands and throt­tled en­tire in­dus­tries, but the on­ly ef­fect it had on bio­phar­ma ven­ture in­vest­ing was to help tur­bocharge the field to gid­dy new heights.

Be­low you’ll find the new top 100 ven­ture in­vestors in the in­dus­try, ranked by the num­ber of deals they were pub­licly in­volved in, as tracked by Deal­For­ma chief Chris Doko­ma­ji­lar. The num­bers mas­ter then cal­cu­lat­ed the es­ti­mat­ed amount of mon­ey they put in­to each deal — divvy­ing up the cash by the num­ber of play­ers — to in­di­cate how they man­aged their syn­di­cates.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.